Double PALB2 and BRCA1/BRCA2 mutation carriers are rare in breast cancer and breast-ovarian cancer syndrome families from the French Canadian founder population

Ancot,Frédéric; Arcand,Suzanna  L.; Mes‑Masson,Anne‑Marie; Provencher,Diane  M.; Tonin,Patricia  N.

doi:10.3892/ol.2015.3123

Double PALB2 and BRCA1/BRCA2 mutation carriers are rare in breast cancer and breast-ovarian cancer syndrome families from the French Canadian founder population

Authors:
- Frédéric Ancot
- Suzanna L. Arcand
- Anne‑Marie Mes‑Masson
- Diane M. Provencher
- Patricia N. Tonin
View Affiliations

Affiliations: Department of Human Genetics, McGill University, Montreal, QC H3G1A4, Canada, Research Institute of The McGill University Health Centre, Montreal, QC H3G1A4, Canada, Research Centre of The University of Montreal Hospital Centre/Montreal Cancer Institute, Montreal, QC H3G1A4, Canada
Published online on: April 20, 2015 https://doi.org/10.3892/ol.2015.3123
Pages: 2787-2790

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

French Canadian families with breast cancer and breast-ovarian cancer syndrome harbor specific BRCA1, BRCA2 and PALB2 germline mutations, which have been attributed to common founders. Mutations in these genes confer an increased risk to breast and ovarian cancers, and have been identified to play a role in and directly interact with the common homologous recombination DNA repair pathways. Our previous study described the case of a female diagnosed with breast cancer at 45 years old, who harbored the PALB2:c.2323C>T [p.Q775X] and BRCA2:c.9004G>A [p.E3002K] germline mutations, which have been found to recur in the French Canadian cancer families. As the frequency of double heterozygous carriers of breast‑ovarian cancer susceptibility alleles is unknown, and due to the possibility that there may be implications for genetic counseling and management for these carriers, the present study investigated the co‑occurrence of BRCA1/BRCA2 and PALB2 mutations in the French Canadian cancer families. The PALB2:c.2323C>T [p.Q775X] mutation, which is the only PALB2 mutation to have been identified in French Canadian cancer families, was screened in 214 breast cancer cases and 22 breast‑ovarian cancer cases from 114 BRCA1/BRCA2 mutation‑positive French Canadian breast cancer (n=61) and breast‑ovarian cancer (n=53) families using a tailored polymerase chain reaction‑based TaqMan® SNP Genotyping Assay. No additional PALB2:c.2323C>T [p.Q775X] mutation carriers were identified among the BRCA1/BRCA2 mutation carriers. The results suggest that carriers of the PALB2:c.2323C>T [p.Q775X] mutation rarely co‑occur in French Canadian breast cancer and breast‑ovarian cancer families harboring BRCA1 or BRCA2 mutations.

View Figures

View References

1	Foulkes WD, Ghadirian P, Akbari MR, et al: Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women. Breast Cancer Res. 9:R832007. View Article : Google Scholar : PubMed/NCBI
2	Tonin PN, Mes-Masson AM, Futreal PA, et al: Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet. 63:1341–1351. 1998. View Article : Google Scholar : PubMed/NCBI
3	Oros KK, Ghadirian P, Greenwood CM, et al: Significant proportion of breast and/or ovarian cancer families of French Canadian descent harbor 1 of 5 BRCA1 and BRCA2 mutations. Int J Cancer. 112:411–419. 2004. View Article : Google Scholar : PubMed/NCBI
4	Laberge AM, Michaud J, Richter A, et al: Population history and its impact on medical genetics in Quebec. Clin Genet. 68:287–301. 2005. View Article : Google Scholar : PubMed/NCBI
5	Scriver CR: Human genetics: lessons from Quebec populations. Annu Rev Genomics Hum Genet. 2:69–101. 2001. View Article : Google Scholar : PubMed/NCBI
6	Lalloo F and Evans DG: Familial breast cancer. Clin Genet. 82:105–114. 2012. View Article : Google Scholar : PubMed/NCBI
7	Ghadirian P, Robidoux A, Zhang P, et al: The contribution of founder mutations to early-onset breast cancer in French-Canadian women. Clin Genet. 76:421–426. 2009. View Article : Google Scholar : PubMed/NCBI
8	Tischkowitz M, Sabbaghian N, Hamel N, et al: Contribution of the PALB2 c.2323C>T [p.Q775X] founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent. BMC Med Genet. 14:52013. View Article : Google Scholar : PubMed/NCBI
9	Cavallone L, Arcand SL, Maugard CM, et al: Comprehensive BRCA1 and BRCA2 mutation analyses and review of French Canadian families with at least three cases of breast cancer. Fam Cancer. 9:507–517. 2010. View Article : Google Scholar : PubMed/NCBI
10	Roy R, Chun J and Powell SN: BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer. 12:68–78. 2011. View Article : Google Scholar : PubMed/NCBI
11	Tischkowitz M and Xia B: PALB2/FANCN: recombining cancer and Fanconi anemia. Cancer Res. 70:7353–7359. 2010. View Article : Google Scholar : PubMed/NCBI
12	Foulkes WD, Smith IE and Reis-Filho JS: Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010. View Article : Google Scholar : PubMed/NCBI
13	Cote S, Arcand SL, Royer R, et al: The BRCA2 c.9004G>A (E2002 K) [corrected] variant is likely pathogenic and recurs in breast and/or ovarian cancer families of French Canadian descent. Breast Cancer Res Treat. 131:333–340. 2012. View Article : Google Scholar : PubMed/NCBI
14	Pern F, Bogdanova N, Schurmann P, et al: Mutation analysis of BRCA1, BRCA2, PALB2 and BRD7 in a hospital-based series of German patients with triple-negative breast cancer. PLoS One. 7:e479932012. View Article : Google Scholar : PubMed/NCBI
15	Guidugli L, Pankratz VS, Singh N, et al: A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity. Cancer Res. 73:265–275. 2013. View Article : Google Scholar : PubMed/NCBI
16	Tischkowitz M, Xia B, Sabbaghian N, et al: Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci USA. 104:6788–6793. 2007. View Article : Google Scholar : PubMed/NCBI
17	Guenard F, Pedneault CS, Ouellette G, Labrie Y, Simard J, Inherit and Durocher F: Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11 and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer. Genet Test Mol Biomarkers. 14:515–526. 2010. View Article : Google Scholar : PubMed/NCBI
18	Silver DP, Richardson AL, Eklund AC, et al: Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol. 28:1145–1153. 2010. View Article : Google Scholar : PubMed/NCBI
19	Fong PC, Boss DS, Yap TA, et al: Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 361:123–134. 2009. View Article : Google Scholar : PubMed/NCBI
20	Tutt A, Robson M, Garber JE, et al: Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 376:235–244. 2010. View Article : Google Scholar : PubMed/NCBI
21	Hilbers F, Vreeswijk M, van Asperen C and Devilee P: The impact of next generation sequencing on the analysis of breast cancer susceptibility: a role for extremely rare genetic variation? Clin Genet. 84:407–414. 2013. View Article : Google Scholar : PubMed/NCBI